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RESULTSBACKGROUND RESULTS
A Phase I, open label, crossover pharmacokinetic-
pharmacodynamic study was conducted at the Hadassah Clinical
Research Center at the Hebrew University – Hadassah Medical
Center. Nine healthy male volunteers received Entera Bio’s original
oral formulation (OF) and two modified oral formulations (MF-1 and
MF-2) at the fixed dose of 1.5 mg PTH (1-34). Blood samples were
analyzed externally at the Bioanalytical Facility at the University of
East Anglia by validated chemiluminescence based assay on the
IDS-ISYS automated analyzer. Levels of serum calcium were
measured at the clinical laboratory of the Hadassah hospital.
The oral absorption of polypeptides, is characterized by high dose-
to-dose variability due to their low bioavailability. As a result,
maintaining the blood drug levels within the therapeutic window is
very challenging.
An orally administered PTH may have prodigious advantages in the
treatment of bone related disorders due to improved patient
compliance and adherence. However, in order for PTH, a drug
whose specific PK profile is critical for its physiological activity, to be
effective and safe, a consistent and reproducible absorption profile
is essential.
Entera Bio previously developed and presented an oral formulation
of PTH(1-34) that achieved biologically relevant plasma
concentrations of the drug similar to those of the commercial SC
injection. In anticipation of entering more advanced clinical studies,
further development of oral PTH(1-34) formulation was performed
focusing on the control of the drug absorption while minimizing its
variability. The main source of high variability was revealed through
numerous in vitro and preclinical studies resulting in the
development of a novel and improved oral PTH (1-34) formulations.
We now present results from a clinical study utilizing the novel
formulation technology in our oral PTH (1-34) tablets with decreased
inter-subject variability and significantly increased bioavailability.
Similarly, to the drug absorption, pharmacodynamic (PD) response of
the MF-2, presented as the maximal relative increase in albumin
adjusted calcium, in comparison to the OF was improved from
0.07±0.29mg/dL to 0.32±0.24mg/dL (Table 1; Figure 1).
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Figure 2. Maximal PTH (1-34)
plasma concentrations and its
coefficient of variation (Cmax
CV%) following administration
of OF, MF-1 and MF-2, fixed
dose (1.5 mg) oral formulations
of PTH (1-34). Each data point
represents the mean of 9
healthy volunteers.
Figure 1. PK and PD profiles
following the administration of
original and second modified oral
formulation of PTH (1-34) 1.5mg (as
base). Pharmacodynamic profile
expressed as a change in the levels
of albumin adjusted serum calcium.
Each data point represents the
mean of 9 volunteers.
PTH (1-34) formulation n
Cmax
(pg/ml)
Cmax CV 
(%)
AUC
(pg*min/ml)
Serum Calcium
increase (mg/dL)
Original oral formulation (OF) 9 145.1 ± 56 123 3481.2 ± 1843 0.07 ± 0.33
Modified oral formulation 1 (MF-1) 9 374.9 ± 108 91 7976 ± 2556 0.12 ± 0.21
Modified oral formulation 2 (MF-2) 9 480.8 ± 101* 67 11369.4 ± 3719* 0.32 ± 0.33
Table 1. Summary of the main pharmacokinetic and pharmacodynamic parameters
found in the current study. Cmax – the maximal PTH (1-34) plasma concentration; Cmax
CV% - coefficient of variation among the Cmax levels of different volunteers; AUC - total
drug exposure; Serum Calcium increase – change in albumin corrected serum Calcium
relatively to the baseline; All the data presented as a mean ± SE. * statistically
significant in comparison to the original oral formulation of PTH (1-34) (p ≤ 0.05).
Modification of the original Entera Bio oral delivery system of PTH (1-
34) resulted in significantly greater bioavailability and reduced
variability in both the Cmax values and the total drug exposure, AUC.
Presented results focused on Cmax which is the most relevant factor
for determining biological activation of anabolic pathways and
calcium regulation. In the specific case of Entera Bio’s oral PTH (1-
34) delivery system, this essential ‘sharp and short’ exposure to the
drug is achieved due to the fast absorption of the molecule and its
rapid elimination from the body. Similarly, the drug pharmacodynamic
effect was also enhanced by the novel oral formulation of PTH(1-34).
Reduced inter-subject Cmax variability, enhanced bioavailability and
an increased pharmacodynamic effect achieved by the modification
of the dosage form, ensure an improved safety profile of oral PTH (1-
34) on the one hand and biologically effective blood concentrations
of the drug on the other hand. These together with the expected
improvement in compliance significantly enhance the potential of
Entera Bio’s oral PTH(1-34) becoming a clinical success.
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The pharmacokinetic (PK) profile of all oral PTH (1-34) formulations is
characterized by rapid absorption and elimination rates of the drug.
The systemic exposure (AUC) and maximal plasma concentrations
(Cmax) following the administration of the modified oral PTH(1-34)
formulations (MF-1 and MF-2) were noticably higher than AUC and
Cmax of original formulation (OF) (Table 1). Cmax and AUC of the MF-2
were statistically significantly higher than Cmax and AUC of the original
formulation (p = 0.005 and p = 0.01, respectively). Cmax coefficients of
variation (CV%) of the basic oral formulation, modified formulation 1
and modified formulation 2 were 123%, 91% and 67%, respectively
(Table 1; Figure 2).
